Building the case for reimbursement after approval — an AI registered as a device
A trial evaluating the clinical effectiveness and health economic impact of an AI medical device that has already cleared regulatory review, in order to seek reimbursement under national health insurance. The registered intervention is a device.
Trial overview (primary data)
- StatusRecruiting
- ConditionsOsteoporosis
- InterventionsDEVICE: VeriOsteo OP
- SponsorTaichung Veterans General Hospital
- Target enrollment1,180 participants
- Period2026-03-13 〜 2026-11-12
Key points
- The project evaluates clinical effectiveness and health economic impact for smart medical devices that have cleared regulatory review and seek reimbursement.
- It is led by Taichung Veterans General Hospital with two collaborating hospitals in a multi-site network.
- Designs used include randomized controlled trials, before-and-after studies, pragmatic and cluster randomized trials and stepped-wedge designs.
- A health economist analyses cost-effectiveness, quantifying reduced costs, diagnostic efficiency and treatment outcomes.
- The intervention is VeriOsteo OP for osteoporosis, target enrolment 1,180, with completion expected 12 November 2026.
1Approval is the entrance, not the finish
The two registrations so far concerned AI still under validation. This one does not. The AI here has already passed regulatory review. A trial runs all the same, to build the case for paying for it.
2Two reviews, asking different things
Permission to use and payment from public funds are separate judgments. The registration states that integrating new technology into a reimbursement system while securing clinical value and economic benefit is a challenge worldwide.
3How the study is built
- 1A network of sitesTaichung Veterans General Hospital leads, with Kaohsiung Medical University Chung-Ho Memorial Hospital and Changhua Show Chwan Memorial Hospital collaborating
- 2A range of designsRandomized controlled trials, before-and-after studies, pragmatic and cluster randomized trials, and stepped-wedge designs
- 3Economic evaluationA health economist analyses cost-effectiveness, quantifying reduced costs, diagnostic efficiency and treatment outcomes
- 4Standardizing the procedureA framework covering design, data collection, statistical analysis, economic evaluation and ethical review
What marks this registration is that standardizing the assessment procedure itself is among its aims. It is not only evaluating a device but building the way such evaluation is done.
4The device box
Only 14.6% of these AI trials are registered as a device. Approval does not settle which box a registration falls into. The next article takes up an AI registered as a behavioural intervention.
Why it matters
That a device may be used and that public funds will pay for it are separate judgments requiring different evidence: the first concerns safety and performance, the second whether the cost is warranted. That is why a trial is mounted after approval, and that this registration also aims to standardize the assessment procedure reflects an expectation that the same judgment will keep recurring.
FAQ
Why run a trial on an approved device?
How does regulatory review differ from a reimbursement decision?
What is the standardized impact assessment framework?
Sources (primary)
Source: ClinicalTrials.gov (U.S. NIH/NLM, public domain). This site does not provide medical advice. Verify the latest and exact details with the official source. This site is not endorsed or certified by the NIH/NLM.
- ClinicalTrials.gov (study record, original)
- NCT ID: NCT07620834